Remain invested in Biocon: SP Tulsian

SP Tulsian of sptulsian.com told CNBC-TV18, "If Biocon issues bonus which is may be in two years down the line is just an arithmetical adjustment. Suppose if they give one-to-one bonus, price ruling at that point of time is Rs 800, it will get ex-bonus and it will start moving up from there."

He further added, "The Q2 numbers have really been very good. I think the FY14 EPS is likely to be anywhere between 21-22. This is a cash rich company having Rs 800-900 crore in cash. It has a very strong pipeline in biotech space; they are into cancer drugs, oral insulin. Investor can remain invested in the stock with a view of 10 years. Still if you want some alternative one could be Cipla and second could be Glenmark."